Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer
Diagnostics · 12.08.2026 · 16 (16) · 2536
DOI: 10.3390/diagnostics16162536 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 12.08.2026. Verfasst von Yeongjoo Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, Department of Radiology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591,…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, FutureChem (South Korea), Korean government.
Abstract (Originalsprache)
Background
This study aimed to evaluate the association between the uptake on F-18 florastamin PET/CT, which targets the prostate-specific membrane antigen (PSMA), and the histopathological grade of the primary tumor in newly diagnosed prostate cancer patients.
Methods
As a subset analysis of a phase III multicenter trial of florastamin PET/CT in East Asian men, the data from a single institution of pathologically confirmed prostate cancer cases were reviewed. The maximum standardized uptake value (SUVmax) was measured from the primary tumor on florastamin PET/CT images of 110 participants. The International Society of Urological Pathology (ISUP) grade group obtained from surgery or biopsy was classified into three risk groups: low (ISUP 1), intermediate (ISUP 2–3), or high (ISUP 4–5). Correlation was tested between the SUVmax of the prostate cancer and the ISUP-based risk. The PSA level and Prostate Imaging Reporting and Data System (PIRADS) score from MRI were also assessed for association with the SUVmax and ISUP-based risk.
Results
The SUVmax of the primary tumor and the PSA level showed significant positive correlation with the ISUP-based risk (ρ = 0.541, p < 0.001; ρ = 0.328, p = 0.001, respectively). The tumor SUVmax increased with higher PIRADS scores (ρ = 0.516, p < 0.001).
Conclusions
The SUVmax of the primary tumor on florastamin PET/CT was associated with the ISUP-based risk in East Asian men with prostate cancer, suggesting that it could be an imaging biomarker of tumor aggressiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nuclear Medicine, Department of Radiology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Research Institute of Labeling, FutureChem Co., Ltd., Seoul 04794, Republic of Korea.
- Department of Urology, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea.
ORCID-Profile: Yeongjoo Lee, Joo Hyun O, Chansoo Park, Dongho Shin, Hyong Woo Moon, Ji Youl Lee
Förderung
- National Research Foundation of Korea
- FutureChem (South Korea)
- Korean government
- Imdang Scholarship & Cultural Foundation
- FutureChem Co., Ltd.
Zitieren
APA
Lee, Y., O, J. H., Ha, S., Park, C., Shin, D., Moon, H. W., & Lee, J. Y. (2026). Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer. Diagnostics, 16(16), 2536. https://doi.org/10.3390/diagnostics16162536
Vancouver
Lee Y, O JH, Ha S, Park C, Shin D, Moon HW, et al. Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer. Diagnostics. 2026;16(16):2536. doi:10.3390/diagnostics16162536
BibTeX
@article{Lee2026,
author = {Lee, Yeongjoo and O, Joo Hyun and Ha, Seunggyun and Park, Chansoo and Shin, Dongho and Moon, Hyong Woo and Lee, Ji Youl},
title = {Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {16},
pages = {2536},
doi = {10.3390/diagnostics16162536}
}
EUVIMED